AstraZeneca PLC (AZNCF)
130.24
+1.04
(+0.80%)
USD |
OTCM |
Nov 14, 16:00
AstraZeneca Net Income (Quarterly): 1.927B for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 1.927B |
| March 31, 2024 | 2.179B |
| December 31, 2023 | 960.00M |
| September 30, 2023 | 1.374B |
| June 30, 2023 | 1.818B |
| March 31, 2023 | 1.803B |
| December 31, 2022 | 901.00M |
| September 30, 2022 | 1.64B |
| June 30, 2022 | 360.00M |
| March 31, 2022 | 386.00M |
| December 31, 2021 | -347.00M |
| September 30, 2021 | -1.652B |
| June 30, 2021 | 550.00M |
| March 31, 2021 | 1.561B |
| December 31, 2020 | 1.012B |
| September 30, 2020 | 648.00M |
| June 30, 2020 | 756.00M |
| March 31, 2020 | 780.00M |
| December 31, 2019 | 313.00M |
| September 30, 2019 | 299.00M |
| June 30, 2019 | 130.00M |
| March 31, 2019 | 593.00M |
| December 31, 2018 | 1.034B |
| September 30, 2018 | 431.00M |
| June 30, 2018 | 350.00M |
| Date | Value |
|---|---|
| March 31, 2018 | 340.00M |
| December 31, 2017 | 1.301B |
| September 30, 2017 | 686.00M |
| June 30, 2017 | 477.00M |
| March 31, 2017 | 537.00M |
| December 31, 2016 | 1.842B |
| September 30, 2016 | 1.014B |
| June 30, 2016 | -3.00M |
| March 31, 2016 | 646.00M |
| December 31, 2015 | 808.00M |
| September 30, 2015 | 770.00M |
| June 30, 2015 | 697.00M |
| March 31, 2015 | 550.00M |
| December 31, 2014 | -321.00M |
| September 30, 2014 | 254.00M |
| June 30, 2014 | 796.00M |
| March 31, 2014 | 504.00M |
| December 31, 2013 | -524.00M |
| September 30, 2013 | 1.246B |
| June 30, 2013 | 823.00M |
| March 31, 2013 | 1.011B |
| December 31, 2012 | 1.507B |
| September 30, 2012 | 1.511B |
| June 30, 2012 | 1.597B |
| March 31, 2012 | 1.625B |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-1.652B
Minimum
Sep 2021
2.179B
Maximum
Mar 2024
893.11M
Average
901.00M
Median
Dec 2022
Net Income (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | 69.52M |
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | -42.96M |
| NuCana PLC | -8.826M |
| Autolus Therapeutics PLC | -58.27M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 12.94B |
| Total Expenses (Quarterly) | 10.19B |
| EPS Diluted (Quarterly) | 1.24 |
| Enterprise Value | 227.21B |
| Gross Profit Margin (Quarterly) | 83.13% |
| Profit Margin (Quarterly) | 14.89% |
| Earnings Yield | 3.18% |
| Operating Earnings Yield | 4.83% |
| Normalized Earnings Yield | 3.468 |